ADCC-Enhanced Anti-Human CD20 (REGN1979) Antibody, a biobetter (CAT#: BioBet-CB-058LX) Datasheet

Target
CD20
Isotype
IgG4
Description
ADCC-Enhanced Anti-Human CD20 (REGN1979) Antibody is a glycosylation-modified anti- therapeutic antibody. Creative Biolabs' Afuco™ technology platform allows control of glycosylation level, thereby achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD20
Full Name
Membrane spanning 4-domains A1
Background
This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein. [provided by RefSeq, Jul 2008]
Alternative Names
B1; S7; Bp35; CD20; FMC7; CVID5; MS4A2; LEU-16
Gene ID
UniProt ID
Field of research
Cell Biology, Immunology,
Trade name
REGN1979
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
REGN1979
Host
Human
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human CD20 (REGN1979) Antibody is derived from clone REGN1979, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the CD20, and it is intended for the research of Follicular lymphoma.
Indication
Follicular lymphoma

Similar to the parental antibody REGN1979, ADCC-Enhanced Anti-Human CD20 (REGN1979) Antibody targets to the antigen CD20, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK